48 articles in this topic
Arvinas' vepdegestrant becomes the first PROTAC to clear Phase 3 trials, targeting disease proteins for destruction rather than just blocking them.
With brensocatib now approved, researchers are mapping the next wave of therapies for this chronic, underserved lung disease.
Emerging neurotech approaches are shifting focus from failed drug targets toward gene therapy, bioelectronics, and AI-guided diagnostics.
A new class of cancer drugs targets replication stress — a core vulnerability in tumor cells — potentially opening a long-sought therapeutic window.
The latest cancer therapies unveiled at ASCO 2026 signal major shifts in how oncologists detect, treat, and manage cancer long-term.
A new class of drugs called proximity degraders can destroy disease-causing proteins once considered untreatable. Here's what's coming next.
Xenotransplantation, 3D bioprinting, and stem cell therapies are converging to solve the global organ shortage crisis.
The FDA greenlights a new antibody-drug conjugate for aggressive breast cancer, expanding first-line treatment options for patients.
A new wave of antidepressants is targeting patients who don't respond to standard treatments, with implications for brain health and longevity.
Wave Life Sciences shares early trial data on an RNA editing treatment for alpha-1 antitrypsin deficiency, targeting monthly dosing.
A second wave of RAS-targeting therapies is reshaping cancer treatment, with implications for longevity through better tumor control.
AstraZeneca's baxdrostat wins FDA approval for hypertension, offering a novel mechanism for patients uncontrolled on existing therapies.
